HomeAbout Investor AwarenessClient ServicesClient Success StoriesManagement TeamClient ProfilesContact Us

Client Profiles


BioRestorative TherapiesBioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. (BRTX) develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The Company has two dynamic Cell-Based Therapeutic Programs: Extraordinary Technology to Treat Chronic Lumbar Disc Disease (Bulging and Herniated Spinal Discs) and Metabolic Disorders (Diabetes); Encouraging Human Data for Disc Program.
Yahoo Data and NewsCompany Web SiteCompany Profile

Yahoo Data and News
 Yahoo Finance Data & News
Company Profile Company Profile (PDF)
Company Web Site Company Web Site

News and Updates

Pressure BioSciences to Participate in SCIEX Workshop
SOUTH EASTON, Mass., March 14, 2016 -- Pressure BioSciences, Inc. (PBIO) ("PBI" and the "Company"), a leader in the development and sale of broadly enabling pressure cycling technology ("PCT")-based sample preparation solutions to the worldwide life sciences industry, today announced that SCIEX, a global leader in life science analytical technologies, will present and lead a precision medicine workshop on "New Innovations Towards Industrialized Proteomics" at the annual conference of the US Human Proteome Organization ("US HUPO"). US HUPO is being held from March 13-16 in Boston, MA. (full story)

Pressure BioSciences Closes $550,000 First Tranche of $5 Million PIPE Over-Subscription Amount
SOUTH EASTON, Mass., March 1, 2016 /PRNewswire/ -- Pressure BioSciences, Inc. (PBIO) ("PBI" and the "Company"), a leader in the development and sale of broadly enabling, pressure cycling technology ("PCT")-based sample preparation solutions to the worldwide life sciences industry, today announced it has closed the first tranche of the over-subscription amount of its $5 million Private Placement (the "Offering") following the receipt of $550,000 in gross proceeds from the sixth overall closing of the Offering. This closing increased the total amount raised in the Offering to $5,560,000.
(full story)

BioRestorative Therapies Deepens Board of Directors with Addition of Robert B. Catell
MELVILLE, N.Y., February 23, 2016 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BRT" or the “Company") (BRTX), a life sciences company focused on stem cell-based therapies, today announced that it has deepened its Board of Directors with the appointment of Robert B. Catell. (full story)

More Articles

Upcoming Events

There are no events to display at this time.
Complete Events List

Cleveland BioLabsCleveland BioLabs
Cleveland BioLabs, Inc. is an innovative biopharmaceutical company seeking to develop first-in-class pharmaceuticals designed to address diseases with significant medical need. CBLI’s programs are focused on the use of novel toll-like receptor agonists to activate the immune system for therapeutic benefit. The Company's most advanced product candidate is entolimod, which is being developed as a radiation countermeasure and an immunotherapy for oncology and other indications. The company maintains strategic relationships with the Cleveland Clinic and Roswell Park Cancer Institute.

CBLI is focused on achieving two major objectives:

  1. Commercializing entolimod as a medical radiation countermeasure through pre-Emergency Use Authorization.
  2. Achieving clinical validation and partnerships for cancer immunotherapies and vaccine adjuvant technology.
Yahoo Data and NewsCompany Web Site

CorbusCorbus Pharmaceuticals, Inc.
Corbus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat life threatening ("orphan") inflammatory-fibrotic diseases with clear unmet needs. The Company’s lead product Resunab is a first- in-class oral anti-inflammatory expected to commence Phase-2a clinical trials for the treatment of cystic fibrosis and scleroderma pending FDA approval of IND.

About Resunab™
Resunab is a novel synthetic oral drug with unique anti-inflammatory and anti-fibrotic activity. Pre-clinical and Phase 1 studies have shown Resunab to have an excellent safety profile in humans and promising potency. Resunab binds to the CB2 receptor of immune cells and triggers a process known as "inflammatory resolution", in effect turning chronic inflammation "off."
Yahoo Data and NewsCompany Web Site

Pressure BioSciences, Inc.Pressure BioSciences, Inc.
Pressure BioSciences, Inc. is a leader in the development and sale of broadly enabling, pressure cycling technology ("PCT")-based sample preparation solutions to the worldwide life sciences industry. The Company develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use our products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and forensic applications.
Yahoo Data and NewsCompany Web Site




  Disclaimer     Financial Glossary

©2013 Investor Awareness, Inc. All rights reserved